遠大醫藥集團(00512.HK)授出逾2.2億港元可換股借款
遠大醫藥集團(00512.HK)宣布,全資附屬遠大香港上周五(1日)再向Sirtex HoldCo提供第二份可換股借款協議,累計本金為 2,866萬美元,相等於約2.24億港元。借款協議為期一年,利率 7.4%。
與第一份可換股借款協議一樣,第二份協議亦可兌換為Sirtex HoldCo的股本權益。假設第一份可換股借款及第二份可換股借款全部兌換,遠大香港將可擁有Sirtex HoldCo被擴大已發行股本約 11.83%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.